Aqemia

Aqemia, a pharmatech company, was founded in 2019 by CEO Maximilien Levesque and COO Emmanuelle Martiano, as a spin-off from the École Normale Supérieure (ENS) in Paris. The company is built on 8 years of research in quantum-inspired physics.

The company's core business is to accelerate the discovery of new drug candidates. It has developed a platform that combines quantum and statistical mechanics algorithms with artificial intelligence. This technology aims to predict the affinity between a drug candidate and a therapeutic target, thereby speeding up the drug discovery process. Aqemia's platform is used for both small molecules and biologics.

The business model of Aqemia involves forming research collaborations with pharmaceutical and biotechnology companies. In these collaborations, Aqemia leverages its platform to identify promising drug candidates for specific therapeutic targets provided by its partners. The company receives upfront payments, milestone payments based on the progress of the drug candidates, and royalties on the sales of the drugs that are successfully developed and commercialized.

Aqemia also has its own internal drug discovery pipeline, which is focused on oncology and immuno-oncology. The company is developing a portfolio of proprietary drug candidates, which it may choose to develop on its own or in partnership with other companies.

Keywords: drug discovery, pharmatech, quantum physics, artificial intelligence, oncology, immuno-oncology, therapeutic molecules, drug candidates, small molecules, biologics